PRAGMA Therapeutics Competitors and Similar CompaniesClear all
PRAGMA Therapeutics's competitors and similar companies include Alnylam, Oxurion, Sorrento Therapeutics and Biosearch Life.
 PRAGMA Therapeutics PRAGMA Therapeutics is a biotech company dedicated to the discovery and development of treatments for stress-related disorders. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  Biosearch Life Biosearch Life is a biotechnology company that provides probiotics, omega-3 fatty acids, and botanical extracts. | |
Founding Date | Founding Date 2015 | Founding Date 2002 | Founding Date 1991 | Founding Date 2006 | Founding Date 2000 |
Type | Type Private | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Archamps, FR HQ | Locations Leuven, BE HQ Dublin 8, IE | Locations San Diego, US HQ San Diego, US | Locations Granada, ES HQ Madrid, ES | |
Employees | Employees 2 | Employees 1,32324% increase | Employees 785% increase | Employees 31019% decrease | Employees 91 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 36.5 b | Valuation ($) 626.1 k | Valuation ($) 1.5 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) €555k (FY, 2025) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $677.2m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $3b (FY, 2025) | Gross profit €937k (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income $313.7m (FY, 2025) | Net income (€3.7m) (FY, 2025) | Net income ($577.8m) (FY, 2022) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised $ 1.7m | Total funding raised $ 1.5b | Total funding raised $ 3.9m | Total funding raised $ 42.6m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companyOxurion
HQ
Leuven, BE
Employees
78↑ 5% increase
Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyBiosearch Life
HQ
Granada, ES
Biosearch Life is a biotechnology company that provides probiotics, omega-3 fatty acids, and botanical extracts.
View company